A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: A phase II, randomized, double-dummy, controlled trial

14 p | 10 | 2

Study protocol of the TEC-ORL clinical trial: A randomized comparative phase II trial investigating the analgesic activity of capsaicin vs Laroxyl in head and neck Cancer survivors presenting with neuropathic pain sequelae

6 p | 2 | 2

Randomized placebo-controlled doubleblind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: A study protocol

8 p | 6 | 2

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

11 p | 14 | 2

Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: A randomized controlled trial

9 p | 13 | 2

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: An ancillary study derived from a randomized clinical trial

10 p | 7 | 1

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

7 p | 11 | 1

Breast ductal lavage for biomarker assessment in high risk women: Rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo

10 p | 6 | 1

Fool’s gold, lost treasures, and the randomized clinical trial

19 p | 15 | 0